PI3K, AKT and MEK inhibition using specific small kinase inhibitors has been proposed as an effective therapy in several tumor types, including mCRPC (Davies et al., 2012; Hancox et al., 2015; Park et al., 2015). Here, MAP2K7 is linked to neoplasm.